CellSeed Inc.
7776・Growth Market・Precision Instruments
Regenerative Medicine Support Business
CellSeed's core revenue-generating segment providing manufacturing and sales of Temperature-Responsive Cell Culture Devices and Regenerative Medicine CDMO services
| Period | Current | Previous | Change |
|---|---|---|---|
| Segment sales (cumulative Q1, FY2026 ending December 2026) | ¥10 million | ¥26 million (cumulative Q1, FY2025 ending December 2025) | ↓ |
| Segment operating loss (cumulative Q1, FY2026 ending December 2026) | -¥36 million | -¥27 million (cumulative Q1, FY2025 ending December 2025) | ↓ |
| Segment sales (full year, FY2025 ending December 2025) | ¥82 million | － | — |
| Segment operating loss (full year, FY2025 ending December 2025) | -¥105 million | － | — |
Business Details
This segment centers on the research and development, manufacturing, and sales of Temperature-Responsive Cell Culture Devices and their derivative products, and also operates Regenerative Medicine Contract Development and Manufacturing (CDMO) Services utilizing a Cell Processing Center (CPC). Domestically, the company collaborates with existing distributors, while overseas, despite being affected by geopolitical turmoil, new promotional measures are being prepared. In the first quarter of FY2026 (ending December 2026), sales continued to be sluggish at ¥10 million (down ¥15 million year-on-year).
Recent Overview
Continued weakness in overseas markets led to a roughly 60% year-on-year decline in Q1 sales
Cumulative Q1 FY2026 (ending December 2026) sales in the Regenerative Medicine Support Business were ¥10 million (down ¥15 million year-on-year), with an operating loss of ¥36 million (a widening of ¥9 million year-on-year). The prolonged political and geopolitical turmoil in overseas markets was the main cause of the sales decline. Domestically, the company gave a poster presentation at the 25th Annual Meeting of the Japanese Society for Regenerative Medicine held in March 2026 to raise awareness of its device products, while also preparing new promotional measures for overseas markets to replace conventional approaches. Regarding CDMO services, the company updated its website and is focusing on acquiring new contract projects.
Key Products
Growth Drivers
- Expanding sales of device products and raising awareness through academic activities by strengthening collaboration with domestic distributors (such as Funakoshi)
- Expansion of the Regenerative Medicine CDMO business: acquiring new contract projects from medical institutions and companies (enhanced appeal through website renewal)
- Expanding the customer base through new product development (improved usability, optimized culture surfaces, products supporting clinical research stages)
- Export recovery (in European and Asian markets) through implementation of new overseas promotional measures
- Supplying products to new markets aimed at mass culture of research cells
Risks
- Risk of continued sluggish overseas sales due to budget cuts at U.S. research institutions and geopolitical turmoil in Europe and the Middle East
- High dependence on sales to Thermo Fisher Scientific Inc. (down to 39.1% in the previous full fiscal year but still a major customer)
- Intensifying competition for CDMO contract projects and uncertainty in the number of contracts obtained
- Constraints on contract capacity due to difficulty in securing and training cell culture technicians
- Risk of impairment losses on segment assets (¥52 million recorded in full-year FY2025 ending December 2025)
Last updated: March 26, 2026